Eurofins Viracor, LLC, a leader in testing for infectious disease, immunology, and allergy, announced that it has entered into an exclusive license agreement with Cornell University to commercialize several ground-breaking and novel assays aimed at transforming the clinical management of COVID-19 and transplant patients impacted from tissue damage and infections.
Surgical biopsy is critical in tracking damage of COVID-19 in the body, but the procedure can be painful and costly to the patient. The Cornell University team, led by Dr. Iwijn De Vlaminck, an associate professor at the Meinig School of Biomedical Engineering, has developed an alternative to biopsy – a novel, noninvasive blood test to measure organ injury from COVID-19. The test uses circulating cell-free DNA (cfDNA) to gauge the damage that COVID-19 inflicts on cells, tissues, and organs.
Learn more about Eurofins Viracor and Cornell University Sign Exclusive Licensing Agreement.
